TWi Biotechnology, Inc. (TPEX:6610)
Taiwan · Delayed Price · Currency is TWD 40.95
+0.40 (0.99%)
Sep 8, 2026, 1:59 PM CST
TWi Biotechnology Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 110.85 | 263.72 | 340.46 | 151.83 | 160.4 | 188.84 |
Short-Term Investments | - | - | 16 | 171.85 | - | 34.3 |
Cash & Short-Term Investments | 110.85 | 263.72 | 356.46 | 323.69 | 160.4 | 223.14 |
Cash Growth | -66.67% | -26.02% | 10.13% | 101.80% | -28.12% | 5.10% |
Other Receivables | 0.8 | 1.25 | 0.97 | 0.44 | 0.57 | 4.13 |
Receivables | 0.8 | 1.25 | 0.97 | 0.44 | 0.57 | 4.13 |
Prepaid Expenses | 2.74 | 3.53 | 1.96 | - | 1 | 1.41 |
Other Current Assets | 1 | - | 32.8 | 0.8 | - | - |
Total Current Assets | 115.38 | 268.49 | 392.19 | 324.93 | 161.97 | 228.68 |
Property, Plant & Equipment | 1.98 | 3.25 | 6.56 | 9.96 | 5.75 | 9.54 |
Long-Term Investments | - | - | - | - | 1 | 1 |
Other Intangible Assets | 410.96 | 426.62 | 453.03 | 39.25 | 45.25 | 51.81 |
Other Long-Term Assets | 24.56 | 25.21 | 24.46 | 22.72 | 20.34 | 20.01 |
Total Assets | 552.88 | 723.58 | 876.24 | 396.85 | 234.31 | 311.04 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accrued Expenses | 57.87 | 73.01 | 35.18 | 32.45 | 10.67 | 9 |
Short-Term Debt | - | - | 10 | - | - | - |
Current Portion of Leases | 1.6 | 2.72 | 2.66 | 2.37 | 2.53 | 2.5 |
Other Current Liabilities | 13.3 | 14.42 | 14.74 | 12.64 | 12.43 | 15.45 |
Total Current Liabilities | 72.76 | 90.15 | 62.58 | 47.45 | 25.63 | 26.95 |
Long-Term Leases | - | 0.23 | 2.95 | 5.6 | - | 2.53 |
Long-Term Unearned Revenue | 2.76 | 2.76 | 2.76 | 2.76 | 2.76 | 2.76 |
Total Liabilities | 75.52 | 93.14 | 68.29 | 55.81 | 28.39 | 32.24 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 2,056 | 2,036 | 876.29 | 877.94 | 678.34 | 674.34 |
Additional Paid-In Capital | 451.54 | 433.21 | 936.25 | - | 830.76 | 830.5 |
Retained Earnings | -2,023 | -1,839 | -1,637 | -1,472 | -1,302 | -1,226 |
Comprehensive Income & Other | -6.91 | - | 632.11 | 935.48 | -1.19 | - |
Shareholders' Equity | 477.35 | 630.44 | 807.96 | 341.04 | 205.92 | 278.8 |
Total Liabilities & Equity | 552.88 | 723.58 | 876.24 | 396.85 | 234.31 | 311.04 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.6 | 2.95 | 15.6 | 7.97 | 2.53 | 5.02 |
Net Cash (Debt) | 109.25 | 260.77 | 340.86 | 315.72 | 157.87 | 218.11 |
Net Cash Growth | -66.72% | -23.50% | 7.96% | 99.98% | -27.62% | 6.48% |
Net Cash Per Share | 0.53 | 1.34 | 1.86 | 4.31 | 2.34 | 3.23 |
Filing Date Shares Outstanding | 205.58 | 203.63 | 87.63 | 87.79 | 67.83 | 67.43 |
Total Common Shares Outstanding | 205.58 | 203.63 | 87.63 | 87.79 | 67.83 | 67.43 |
Working Capital | 42.62 | 178.34 | 329.61 | 277.48 | 136.34 | 201.73 |
Book Value Per Share | 2.32 | 3.10 | 9.22 | 3.88 | 3.04 | 4.13 |
Tangible Book Value | 66.39 | 203.82 | 354.93 | 301.79 | 160.67 | 226.99 |
Tangible Book Value Per Share | 0.32 | 1.00 | 4.05 | 3.44 | 2.37 | 3.37 |
Machinery | 3.77 | 3.65 | 10.55 | 10.25 | 10.25 | 10.25 |
Leasehold Improvements | - | - | - | 4.85 | 4.85 | 4.85 |